Announcements Trials
Browse Landscape

Phase

Phase 2 46Phase 1 35Phase NA 30Phase 3 24Phase 1/2 13Phase 2/3 4Phase EARLY_PHASE1 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Squamous Cell Carcinoma of Head and Neck 12Neoplasm Metastasis 12Prostatic Neoplasms 11Neoplasms 10Breast Neoplasms 8Stomach Neoplasms 7Recurrence 7Ovarian Neoplasms 7Myasthenia Gravis 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Head and Neck Neoplasms 7Colorectal Neoplasms 6Pancreatic Neoplasms 5Oropharyngeal Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Fatigue 5Urinary Bladder Neoplasms 4Mouth Neoplasms 4Melanoma 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Colonic Neoplasms 4Cholangiocarcinoma 4Rectal Neoplasms 3Peritoneal Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Glioblastoma 3

Interventions

Gemcitabine 3Cisplatin 2Carboplatin 2toripalimab 1disitamab vedotin 1RC48 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Urinary Bladder Neoplasms × 90 days × Clear all
NCT06851663 2026-05-29

Trop2-targeted immunoPET Imaging of Solid Tumors

RenJi Hospital

Phase 2/3 Recruiting
400 enrolled
GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07608224 2026-05-27

HOPE-07-MIBC

West China Hospital

Phase 2/3 Not yet recruiting
240 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07129993 2026-05-14

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Daiichi Sankyo

Phase 2/3 Recruiting
630 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07106762 2026-05-12

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Bristol-Myers Squibb

Phase 2/3 Recruiting
470 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡